Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Receivables (2016 - 2026)

Lexaria Bioscience's Receivables history spans 12 years, with the latest figure at $106043.0 for Q1 2026.

  • Quarterly results put Receivables at $106043.0 for Q1 2026, down 73.17% from a year ago — trailing twelve months through Feb 2026 was $106043.0 (down 73.17% YoY), and the annual figure for FY2025 was $368358.0, up 68.93%.
  • Receivables for Q1 2026 was $106043.0 at Lexaria Bioscience, down from $152057.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $534731.0 in Q4 2023 to a low of $106043.0 in Q1 2026.
  • The 5-year median for Receivables is $218052.0 (2024), against an average of $276412.1.
  • The sharpest move saw Receivables crashed 83.77% in 2022, then surged 189.91% in 2024.
  • Year by year, Receivables stood at $286322.0 in 2022, then soared by 86.76% to $534731.0 in 2023, then crashed by 50.72% to $263491.0 in 2024, then tumbled by 42.29% to $152057.0 in 2025, then crashed by 30.26% to $106043.0 in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $106043.0, $152057.0, and $368358.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.